Skip to content
Evigrade
CriticalSecond-generation systemic triazole antifungal×Antifungal, triazole

Updated · Methodology

Mechanism

Itraconazole strongly inhibits the enzyme CYP3A4, and isavuconazole is a sensitive substrate of this enzyme (itraconazole summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; isavuconazole label, US Food and Drug Administration, FDA). The pair has not been studied directly, but the itraconazole SmPC says that itraconazole is likely to raise isavuconazole levels (AEMPS). The documents give no figures for itraconazole. Ketoconazole, another strong CYP3A4 inhibitor, increased isavuconazole exposure (area under the curve, AUC) by 422%, and lopinavir with ritonavir by 96% (isavuconazole SmPC, European Medicines Agency, EMA). In the other direction, isavuconazole is a moderate CYP3A4 inhibitor and may raise levels of drugs that this enzyme metabolises, and CYP3A4 is the main enzyme that metabolises itraconazole in the liver (EMA, AEMPS). There are no measurements for this direction either.

Symptoms

Higher isavuconazole levels may bring more adverse reactions (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). At three times the usual maintenance dose, headache, dizziness, tingling, numbness in the mouth, sleepiness, poor attention, taste disturbance, dry mouth, diarrhoea, vomiting, flushing, anxiety, agitation, palpitations, fast heart rate, sensitivity to light and joint pain were more frequent (isavuconazole SmPC, EMA, and isavuconazole label, US Food and Drug Administration, FDA). Isavuconazole shortens the QT interval, more so at higher concentrations (EMA). The documents do not say how this effect changes with itraconazole. Both drugs can harm the liver, and the itraconazole SmPC lists the warning signs: loss of appetite, nausea, vomiting, tiredness, abdominal pain and dark urine (itraconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; isavuconazole label, FDA).

Management

The combination is contraindicated. The Spanish and US itraconazole documents name isavuconazole among the drugs that must not be given during itraconazole treatment or for two weeks after it is stopped (itraconazole summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and itraconazole label, US Food and Drug Administration, FDA). The US isavuconazole label contraindicates all strong CYP3A4 inhibitors, and itraconazole is a strong CYP3A4 inhibitor according to its own US label (isavuconazole and itraconazole labels, FDA). The European isavuconazole SmPC is less strict: among strong CYP3A4 inhibitors it contraindicates only ketoconazole. With the others, it keeps the isavuconazole dose unchanged but says to use isavuconazole with caution, because adverse reactions may increase (isavuconazole SmPC, European Medicines Agency, EMA). When switching from itraconazole to isavuconazole, start isavuconazole no earlier than two weeks after stopping itraconazole (AEMPS, FDA). Itraconazole levels fall to almost undetectable within 7–14 days, and they fall even more slowly in liver cirrhosis or with other CYP3A4 inhibitors (itraconazole SmPC, AEMPS). No document gives a waiting time for switching from isavuconazole to itraconazole, only the mean half-life of isavuconazole, 130 hours (isavuconazole label, FDA). Test liver function before and during isavuconazole treatment (FDA), and consider liver monitoring during itraconazole treatment (AEMPS). If signs of liver disease that may be due to the drug appear, stop isavuconazole (FDA) or itraconazole (AEMPS). If the patient has had an allergy to one azole antifungal, prescribe the other with caution (itraconazole SmPC, AEMPS, and isavuconazole SmPC, EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Isavuconazole

Other interactions with Itraconazole